TGen Drug Development (TD2) and Rondaxe Enterprises are to share their respective capabilities in the fields of drug development, regulatory issues, and manufacturing to provide pharma companies with a suite of services. The organizations claim their alliance is designed to bridge the gap between chemistry and translational medicine.
The partnership means Rondaxe will have access to TD2’s tools and services for preclinical support, clinical trials, and regulatory affairs. TD2 will be able to exploit Rondaxe’s expertise in drug development and manufacturing strategies encompassing chemistry and fermentation, drug and analytical development, production, QC, and QA.
TD2 is a wholly owned, nonprofit subsidiary of the Translational Genomic Research Institute. The organization integrates its expertise in clinical and regulatory activities to provide drug development services for oncology-focused biopharma companies. The company describes its "De-Risk" strategy as a comprehensive, multifaceted solution intended to shorten development cycles for anticancer agents and improve their success rates.
Rondaxe is a drug development services company with specialist expertise in areas of chemistry, manufacturing, and control. The firm’s services are designed to help emerging pharmaceutical and biotechnology companies navigate through all phases of the drug development and commercialization process.